Answers are grounded in this paper and cite their sources.
Background: Minocycline improved functional outcomes in EMPHASIS, but timing-related consistency is uncertain. We assessed treatment effects by first-dosing clock time and onset-to-first-dosing interval. Methods: EMPHASIS was a phase 3, multicentre, double-blind, randomised, placebo-controlled trial at 58 Chinese hospitals. Patients aged 18–80 years with acute ischaemic stroke within 72 h and NIHSS 4–25 were assigned 1:1 to oral minocycline or placebo. This prespecified subgroup analysis categorised first-dosing clock time as daytime, evening, or overnight, and onset-to-first-dosing interval as ≤24 h, >24–48 h, or >48 h. The primary outcome was 90-day mRS 0–1. Treatment-by-subgroup interactions were tested in adjusted models. Findings: Between May 19, 2023, and May 20, 2024, 1724 patients were assigned (862 per group). Minocycline increased 90-day mRS 0–1 versus placebo (447/850 [52·6%] vs 403/851 [47·4%]; absolute difference 5·2 percentage points, 95% CI 0·5–10·0; adjusted RR 1·14, 95% CI 1·03–1·25; P=0·012). No significant interaction was detected by first-dosing clock time (P for interaction=0·559) or onset-to-first-dosing interval (P for interaction=0·604). Symptomatic intracranial haemorrhage at 24 h occurred in one minocycline patient and none receiving placebo. Interpretation: We found no statistical evidence that minocycline effects differed by first-dosing clock time or onset-to-first-dosing interval within 72 h; these exploratory findings do not establish an optimal dosing time.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: